# GCC Drug Repurposing Market > GCC Drug Repurposing Market Size, Growth Research Report By Types (Disease-centric, Target-centric, Drug-centric), By Therapeutic Area (Same Therapeutic Area, Different Therapeutic Area) and By Drug Molecules (Biologics, Small Molecule) - Competitor Industry Analysis and Trends Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 14.99% - **2024:** $ 10 Million - **2025:** $ 11.5 Million - **2035:** $ 46.5 Million - **Key Players:** Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), AstraZeneca PLC (GB), Eli Lilly and Company (US), Gilead Sciences Inc (US), Sanofi SA (FR) **Report ID:** MRFR/Pharma/50633-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-drug-repurposing-market-52391 --- ## Market Summary ## **GCC Drug Repurposing Market Overview** As per MRFR analysis, the GCC Drug Repurposing Market Size was estimated at 15 (USD Million) in 2023. The GCC Drug Repurposing Market Industry is expected to grow from 16.9(USD Million) in 2024 to 80 (USD Million) by 2035. The GCC Drug Repurposing Market CAGR (growth rate) is expected to be around 15.181% during the forecast period (2025 - 2035) ### **Key GCC Drug Repurposing Market Trends Highlighted** The GCC Drug Repurposing Market is experiencing significant growth driven by a combination of factors such as rising healthcare costs, the urgent need for effective treatments, and advancements in biotechnology. Governments in the GCC region are increasingly investing in healthcare infrastructure, which creates a conducive environment for drug development and repurposing initiatives. Additionally, the prevalence of chronic diseases and an aging population further propel the demand for innovative therapies.  The trend towards collaborative efforts between public and private sectors is also noteworthy, as these partnerships enhance research capabilities and streamline the drug development process.Opportunities to be explored in the GCC market include expanding research collaborations with academic institutions and increasing engagement with pharmaceutical companies that are keen on using existing drugs for new therapeutic purposes. The region's focus on developing a knowledge-based economy is paving the way for stronger research and development activities, particularly in drug repurposing, which could lead to faster approvals and reduced costs for new indications based on existing medications.  Recent trends indicate a growing interest from regulatory bodies in fast-tracking drug repurposing processes, which aligns with global movements to expedite access to essential medicines.Moreover, the COVID-19 pandemic has highlighted the importance of rapidly developing treatments, further boosting efforts in this area. The GCC region is also seeing an increase in digital health solutions that assist in drug repurposing efforts, facilitating better data analysis and patient involvement. Overall, the combination of increased government support, collaborative opportunities, and innovative approaches signals a vibrant future for the drug repurposing market in the GCC. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **GCC Drug Repurposing Market Drivers** ### **Increase in Chronic Diseases** Diabetes and cardiovascular disorders are among the chronic diseases that are becoming more common in the Gulf Cooperation Council areas. The Gulf nations have one of the highest rates of diabetes in the world, with over 29.9% of people having the disease, according to the Gulf Health Council. In the GCC Drug Repurposing Market Industry, this rise fuels demand for cutting-edge therapeutic alternatives, such as medication repurposing.  Furthermore, there is a growing need for alternate treatment made possible by medication repurposing as a result of well-known organizations like the Gulf Cooperation Council (GCC) Health Ministers Council actively supporting health programs to better manage chronic illnesses. ### **Growing Investment in Research and Development** Countries within the Gulf Cooperation Council are significantly investing in Research and Development (R&D) to facilitate advancements in healthcare, particularly in drug development. The GCC region has been increasing its health sector spending, which is reported an increase to approximately 8% of GDP by 2022, according to the World Bank.  This heavy investment fosters an environment conducive to drug repurposing efforts, as pharmaceutical companies and research institutions seek to discover new applications for existing drugs in addressing prevalent health issues.Companies like Saudi Pharmaceutical Industries and Medical Appliances Corporation are actively contributing to this growth by exploring repurposing opportunities. ### **Regulatory Support for Drug Repurposing** The regulatory landscape in the Gulf Cooperation Council has been evolving to support drug repurposing initiatives. Recent policies introduced by the Saudi Food and Drug Authority and other regulatory bodies across the GCC are aimed at expediting the approval process for repurposed drugs. This regulatory facilitation is vital in a region where healthcare demands are high and there is a need for efficient treatment solutions.  By streamlining the processes, these organizations are encouraging pharmaceutical companies to invest in the GCC Drug Repurposing Market Industry, leading to increased availability of repurposed therapies. ### **Rising Awareness of Personalized Medicine** Personalized medicine is gaining traction within the GCC region, aligning with the global trend towards tailored healthcare solutions. A report from the Qatar Biomedical Research Institute indicates that patient-centric approaches can lead to improved treatment outcomes, driving interest in drug repurposing as a method to tailor existing medications to individual patient needs.  Organizations like the Qatar Foundation are advocating for personalized medicine initiatives, further supporting the GCC Drug Repurposing Market Industry as they explore how existing therapies can be adapted for better responses among specific patient populations. ## **GCC Drug Repurposing Market Segment Insights** ### **Drug Repurposing Market Types Insights** The GCC Drug Repurposing Market is poised for significant growth, primarily driven by the diversification within its Types classification, which includes Disease-centric, Target-centric, and Drug-centric approaches. The Disease-centric approach focuses on the identification and development of existing drugs to treat new diseases, which plays a crucial role in addressing the rising incidence of chronic and rare diseases within the Gulf Cooperation Council region. Given the demographic shifts and increasing healthcare demands, such versatility in drug application can lead to cost-effective solutions for patients and healthcare providers alike. Meanwhile, the Target-centric category emphasizes the chemical properties of drugs and their interactions with specified biological targets, enabling the repurposing of well-characterized drugs in a timely manner. This strategy lends itself effectively to accelerating the Research and Development processes, minimizing the risk associated with introducing new medications. Furthermore, the Drug-centric approach systematically assesses existing molecular compounds, harnessing their therapeutic potential in innovative ways.  The ongoing trends of personalized medicine and precision therapies in the GCC highlight the significance of these approaches, as pharmaceutical companies look to maximize the utility of their existing portfolios amidst stringent regulatory environments.Importantly, the GCC region is seeing a push from governments and health authorities to promote innovative healthcare solutions, such as drug repurposing, which is poised to lead to more efficient healthcare systems and greater patient access to treatments.  Overall, the segmentation of the GCC Drug Repurposing Market into these types provides a thorough framework to explore various opportunities while highlighting the drivers, challenges, and growth potentials within this evolving industry landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Drug Repurposing Market Therapeutic Area Insights** The GCC Drug Repurposing Market, particularly within the Therapeutic Area segment, is showcasing significant potential driven by advancements in medical research and the urgent need for cost-effective healthcare solutions. The market segmentation includes both Same Therapeutic Area and Different Therapeutic Area applications, which play essential roles in drug development. The Same Therapeutic Area focuses on leveraging existing medications to treat additional conditions, enhancing drug efficacy while reducing Research and Development timelines.This approach minimizes the risk and costs associated with traditional drug development.  On the other hand, the Different Therapeutic Area emphasizes innovative strategies where previously approved drugs are utilized for entirely new therapeutic purposes, catering to diverse patient needs and expanding market opportunities. As nations in the GCC strive to enhance healthcare systems, understanding the dynamics of the GCC Drug Repurposing Market segmentation aids in addressing public health challenges effectively.  The rising prevalence of chronic diseases and the demand for quick therapeutic solutions are driving growth in these segments, which enables healthcare providers to offer a wider range of treatments, ultimately benefiting patients across the region. ### **Drug Repurposing Market Drug Molecules Insights** The Drug Molecules segment within the GCC Drug Repurposing Market showcases significant potential for growth as the pharmaceutical industry increasingly focuses on innovative treatment solutions. This segment is primarily categorized into Biologics and Small Molecules. Biologics, which include therapeutic proteins and monoclonal antibodies, play a crucial role in targeting specific disease pathways, thus enhancing treatment efficacy. Their ability to modify biological processes makes them vital in the treatment of chronic conditions prevalent in the GCC region, such as diabetes and cancer. On the other hand, Small Molecules are dominating the market due to their versatility and ability to easily penetrate biological membranes, making them effective for a range of diseases. The GCC's emphasis on Research and Development is driving advancements in drug repurposing, leveraging existing drugs for new therapeutic uses. Additionally, government initiatives aimed at enhancing healthcare infrastructure and promoting local drug development are expected to bolster the pharmaceutical landscape in the region. This dynamic environment presents ample opportunities for companies engaged in drug discovery and repurposing, thereby catalyzing the growth of Drug Molecules in the GCC Drug Repurposing Market. ## **GCC Drug Repurposing Market Key Players and Competitive Insights** The GCC Drug Repurposing Market is characterized by its dynamic nature and the strategic maneuvers of key players operating within the region. The exploration of existing drugs for new therapeutic applications presents numerous opportunities, especially as healthcare systems in the GCC countries increasingly emphasize cost efficacy and innovative solutions to combat emerging health challenges. Factors such as an aging population, rising prevalence of chronic diseases, and the demand for rapid treatments are driving the interest in drug repurposing.  Competitive insights reveal that companies are actively investing in research and development to enhance their portfolios, collaborate with local institutions, and navigate regulatory frameworks that are unique to the Gulf Cooperation Council nations.AstraZeneca has established a robust presence in the GCC Drug Repurposing Market by leveraging its extensive experience in biopharmaceuticals and a diverse product range. The company’s strengths lie in its significant investments in innovative research and collaborations with local healthcare organizations, which allow it to identify and develop new therapeutic applications for existing drugs.  AstraZeneca’s capabilities in clinical trials and regulatory approvals within the GCC region have bolstered its ability to bring repurposed treatments to market swiftly. Their strategic focus on respiratory, cardiovascular, and neurodegenerative diseases aligns well with the prevalent health issues in the region, enabling them to effectively cater to the local population's needs.Roche has been a key player in the GCC Drug Repurposing Market, focusing on enhancing healthcare solutions through innovative therapies and personalized medicine. The company boasts a well-established presence backed by a strong portfolio, which includes both diagnostic and therapeutic agents that can be repurposed.  Roche's strengths are reflected in its global access to cutting-edge research, which allows for the identification of new uses for well-known drugs within the local context. The company has made strategic moves through partnerships and potential mergers and acquisitions, enhancing its capabilities in drug repurposing specifically tailored to the GCC market. The integration of its diagnostics expertise with therapeutic offerings positions Roche favorably for further growth in addressing unmet medical needs in the GCC region. ### **Key Companies in the GCC Drug Repurposing Market Include** ## **GCC Drug Repurposing Market Industry Developments** The GCC Drug Repurposing Market has recently seen significant developments, particularly with major pharmaceutical companies like AstraZeneca, Roche, and Gilead Sciences focusing on enhancing their drug repurposing strategies. In June 2023, Merck and Co announced a new initiative aimed at identifying existing medications for potential therapeutic use against emerging diseases in the region. Additionally, in August 2023, Bristol Myers Squibb entered into a partnership with local health authorities to facilitate research collaborations targeted towards early-stage clinical trials of repurposed drugs.  Growth in the market valuation for drug repurposing has been bolstered by the increasing demand for cost-effective treatment alternatives, driven by a surge in chronic diseases across the GCC countries. This has prompted companies like Sanofi and Novartis to accelerate their research efforts in repurposing existing drugs for new disease indications. In the past few years, the GCC has placed strong emphasis on biotechnology and pharmaceutical innovation, with government-backed initiatives supporting Research and Development in this area, thus presenting further opportunities for established and emerging market players alike. ## **GCC Drug Repurposing Market Segmentation Insights** ## Market Drivers ### Rising Prevalence of Chronic Diseases The increasing incidence of chronic diseases in the GCC region is a primary driver for the drug repurposing market. Conditions such as diabetes, cardiovascular diseases, and cancer are becoming more prevalent, necessitating innovative treatment options. The World Health Organization indicates that chronic diseases account for approximately 70% of all deaths globally, a trend mirrored in the GCC. This rising burden creates a demand for cost-effective therapies, making drug repurposing an attractive option. By utilizing existing drugs for new therapeutic indications, healthcare providers can potentially reduce treatment costs and improve patient outcomes. The drug repurposing market is thus positioned to benefit from this growing need for effective management of chronic conditions, as it offers a faster route to market for new treatments, leveraging existing safety profiles of established medications. ### Economic Pressures and Healthcare Costs Economic factors play a crucial role in shaping the drug repurposing market. In the GCC, healthcare expenditures are rising, driven by an increasing population and higher demand for medical services. The drug repurposing market offers a solution to mitigate these costs by providing alternative treatment options that are often less expensive to develop than new drugs. According to recent data, the average cost of bringing a new drug to market can exceed $2.6 billion, while repurposing existing drugs can significantly lower this figure. This economic advantage is particularly appealing to healthcare systems in the GCC, where budget constraints are prevalent. As stakeholders seek to optimize healthcare spending, the drug repurposing market is likely to gain traction as a viable strategy for addressing the financial challenges faced by the region's healthcare systems. ### Patient-Centric Approaches in Healthcare The shift towards patient-centric healthcare models is influencing the drug repurposing market. In the GCC, there is a growing emphasis on personalized medicine and tailored treatment plans that cater to individual patient needs. This trend encourages the exploration of existing drugs for new indications that may better serve specific patient populations. The drug repurposing market aligns well with this approach, as it allows for the rapid adaptation of treatments based on patient feedback and clinical outcomes. By focusing on the unique characteristics of patients, healthcare providers can enhance treatment efficacy and improve overall satisfaction. This patient-centric paradigm is likely to drive interest in drug repurposing, as it offers a pathway to develop therapies that are more aligned with the diverse needs of the population in the GCC. ### Growing Investment in Research and Development Investment in research and development (R&D) is a significant driver of the drug repurposing market. In the GCC, governments and private sectors are increasingly allocating funds to support innovative healthcare solutions. This trend is evident in the establishment of various research initiatives aimed at exploring new uses for existing drugs. The drug repurposing market stands to benefit from this influx of capital, as it enables researchers to conduct clinical trials and gather data on the efficacy of repurposed drugs. Furthermore, the GCC's commitment to enhancing its healthcare infrastructure and fostering innovation creates a conducive environment for drug repurposing initiatives. As R&D investments continue to rise, the potential for discovering new therapeutic applications for existing medications expands, thereby driving growth in the drug repurposing market. ### Regulatory Advancements and Supportive Frameworks Regulatory advancements in the GCC are fostering a more supportive environment for the drug repurposing market. Recent initiatives aimed at streamlining the approval process for repurposed drugs are encouraging pharmaceutical companies to explore this avenue. The drug repurposing market benefits from these regulatory changes, as they reduce the time and resources required to bring new treatments to market. For instance, expedited review processes and simplified clinical trial requirements can significantly enhance the feasibility of repurposing existing medications. As regulatory bodies in the GCC continue to adapt their frameworks to support innovation, the drug repurposing market is likely to experience accelerated growth, enabling quicker access to potentially life-saving therapies for patients. ## Future Outlook The [Drug Repurposing Market](https://www.marketresearchfuture.com/reports/drug-repurposing-market-22086) is projected to grow at a 14.99% CAGR from 2025 to 2035, driven by increasing R&D investments and regulatory support. **New opportunities:** - Development of AI-driven drug screening platforms - Partnerships with biotech firms for accelerated trials - Expansion into niche therapeutic areas with unmet needs By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Disease-centric (Largest) vs. Target-centric (Fastest-Growing) In the GCC drug repurposing market, the largest segment is disease-centric, which comprises a significant share of the overall market. This segment focuses on existing drugs that can be utilized to treat different diseases, thus leveraging prior clinical data and enhancing treatment options efficiently. Target-centric approaches are growing quickly, as they utilize innovative targets for existing drugs, allowing researchers to explore new therapeutic avenues and offering rapid paths to market. The growth of the target-centric segment is driven by advancements in molecular biology and personalized medicine. As healthcare shifts towards tailored treatments, the demand for target-centric repurposing will increase, presenting opportunities for pharmaceutical companies. Additionally, the expanding research into rare diseases and targeted therapies is propelling this segment forward, attracting investment and interest in novel applications of established drugs. Disease-centric (Dominant) vs. Target-centric (Emerging) The disease-centric segment stands out as the dominant force in the GCC drug repurposing market. It strategically capitalizes on the existing drugs to address a variety of diseases, which not only minimizes development costs but also reduces the time taken for market entry. This segment is characterized by a robust framework that allows for patient safety and efficacy given that these drugs have previously undergone extensive testing. In contrast, the target-centric segment is emerging, focusing on innovative therapeutics based on specific molecular targets. As research uncovers new biological pathways, the potential growth of this segment is substantial, driven by the need for personalized healthcare solutions and innovative treatment paradigms. ### By Therapeutic Area: Same Therapeutic Area (Largest) vs. Different Therapeutic Area (Fastest-Growing) In the GCC drug repurposing market, the 'Same Therapeutic Area' segment holds a significant market share as it allows for leveraging existing knowledge and clinical data from familiar therapeutic domains. This segment benefits from the established pipeline of drugs that can be quickly repositioned for additional indications, resulting in lower developmental risks and costs. Conversely, the 'Different Therapeutic Area' segment, while currently smaller, is rapidly gaining momentum due to increasing interest in cross-disciplinary applications where existing treatments can be adapted to target various health conditions, expanding the potential for repurposing. The growth trends in the GCC drug repurposing market reflect a robust increase in both segments. The 'Same Therapeutic Area' is driven by a need for quick and cost-effective solutions to pressing healthcare challenges, while the 'Different Therapeutic Area' segment is fueled by advancements in drug discovery technologies and heightened awareness of multi-indication therapies. This dual approach not only enhances treatment options but also promotes innovation in drug development, positioning both segments for dynamic growth in the forthcoming years. Same Therapeutic Area: Dominant vs. Different Therapeutic Area: Emerging Within the GCC drug repurposing market, the 'Same Therapeutic Area' segment is recognized as the dominant player due to its ability to reuse existing medications for new indications, thereby minimizing the time and costs associated with traditional drug development. This approach is appealing to pharmaceutical companies aiming to maximize their existing portfolios. In contrast, the 'Different Therapeutic Area' segment represents an emerging opportunity where companies explore adapting treatments across various medical categories. This flexibility is critical in addressing diverse health issues and resonates with recent trends towards innovative therapies. As both segments evolve, they create a synergistic effect that enhances the overall market landscape, fostering an environment ripe for groundbreaking advancements and improved patient outcomes. ### By Drug Molecules: Biologics (Largest) vs. Small Molecule (Fastest-Growing) In the GCC drug repurposing market, the market share distribution indicates that Biologics holds a significant portion as the largest segment, driven by the rise of biologics in therapeutic applications. This segment's stronghold is attributed to advancements in biotechnology and a growing demand for targeted therapies, which create substantial opportunities for various drug repurposing strategies. On the other hand, the Small Molecule segment is recognized as the fastest-growing area within this market. This growth is fueled by innovations in drug formulation, increasing partnerships between biotech and pharmaceutical companies, and the strategic focus on repurposing existing small molecules to address unmet medical needs. The evolving landscape presents ample prospects for small molecules to gain traction among healthcare providers. Biologics (Dominant) vs. Small Molecule (Emerging) Biologics are dominating the GCC drug repurposing market due to their ability to target specific disease pathways and their effectiveness in treating complex conditions, such as cancers and autoimmune disorders. This segment benefits from strong regulatory support and increasing investment in biologic therapies. Conversely, Small Molecule drugs, while currently emerging, are quickly gaining importance due to their cost-effectiveness and versatile application potential. With a growing emphasis on personalized medicine and a robust pipeline for drug repurposing, small molecules are expected to play a crucial role in future developments within the GCC drug repurposing market. ## Competitive Benchmarking The drug repurposing market is currently characterized by a dynamic competitive landscape, driven by the increasing need for cost-effective therapeutic solutions and the rapid advancement of biopharmaceutical technologies. Major players such as Pfizer Inc (US), Novartis AG (CH), and AstraZeneca PLC (GB) are strategically positioned to leverage their extensive research capabilities and established market presence. Pfizer Inc (US) has focused on innovation through its robust pipeline of repurposed drugs, while Novartis AG (CH) emphasizes partnerships with academic institutions to enhance its research capabilities. AstraZeneca PLC (GB) is actively pursuing mergers and acquisitions to bolster its portfolio, indicating a trend towards consolidation in the market. Collectively, these strategies contribute to a competitive environment that is increasingly reliant on collaboration and innovation.Key business tactics within the market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for niche players to emerge, yet the dominance of major companies ensures that the market remains competitive and innovative. The collective influence of these key players shapes the market's direction, as they invest in research and development to explore new therapeutic applications for existing drugs. In October Bristol-Myers Squibb Company (US) announced a strategic collaboration with a leading biotechnology firm to explore the repurposing of its existing oncology drugs for rare diseases. This partnership is significant as it not only expands the therapeutic applications of their portfolio but also aligns with the growing trend of personalized medicine. By leveraging its existing assets, Bristol-Myers Squibb Company (US) aims to enhance patient outcomes while potentially reducing development costs associated with new drug discovery. In September Johnson & Johnson (US) launched a new initiative aimed at repurposing its established cardiovascular drugs for the treatment of neurodegenerative diseases. This move reflects a strategic pivot towards addressing unmet medical needs in a rapidly aging population. The initiative underscores the company's commitment to innovation and its ability to adapt its existing products to new therapeutic areas, thereby maximizing the value of its drug portfolio. In August Eli Lilly and Company (US) entered into a partnership with a technology firm to integrate artificial intelligence into its drug repurposing efforts. This collaboration is poised to enhance the efficiency of identifying potential new uses for existing drugs, thereby accelerating the development process. The integration of AI signifies a broader trend within the industry, where technology is increasingly utilized to streamline research and development processes, ultimately leading to faster patient access to new therapies. As of November current competitive trends in the drug repurposing market are heavily influenced by digitalization, sustainability, and the integration of advanced technologies such as AI. Strategic alliances are becoming increasingly vital, as companies recognize the importance of collaboration in driving innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in an increasingly complex and competitive landscape. ## Recent News & Developments The GCC Drug Repurposing Market has recently seen significant developments, particularly with major pharmaceutical companies like AstraZeneca, Roche, and Gilead Sciences focusing on enhancing their drug repurposing strategies. In June 2023, Merck and Co announced a new initiative aimed at identifying existing medications for potential therapeutic use against emerging diseases in the region. Additionally, in August 2023, Bristol Myers Squibb entered into a partnership with local health authorities to facilitate research collaborations targeted towards early-stage clinical trials of repurposed drugs.  Growth in the market valuation for drug repurposing has been bolstered by the increasing demand for cost-effective treatment alternatives, driven by a surge in chronic diseases across the GCC countries. This has prompted companies like Sanofi and Novartis to accelerate their research efforts in repurposing existing drugs for new disease indications. In the past few years, the GCC has placed strong emphasis on biotechnology and pharmaceutical innovation, with government-backed initiatives supporting Research and Development in this area, thus presenting further opportunities for established and emerging market players alike. ## Report Scope | MARKET SIZE 2024 | 10.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 11.5(USD Million) | | MARKET SIZE 2035 | 46.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.99% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Johnson & Johnson (US), AstraZeneca PLC (GB), Eli Lilly and Company (US), Gilead Sciences Inc (US), Sanofi SA (FR) | | Segments Covered | Type, Therapeutic Area, Drug Molecules | | Key Market Opportunities | Emerging technologies enhance drug repurposing efficiency, addressing unmet medical needs in diverse therapeutic areas. | | Key Market Dynamics | Rising interest in drug repurposing driven by regulatory support and technological advancements in the GCC region. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What is the projected market valuation for the GCC drug repurposing market in 2035?** A: The projected market valuation for the GCC drug repurposing market in 2035 is expected to reach $46.5 Million. **Q: What was the market valuation for the GCC drug repurposing market in 2024?** A: The market valuation for the GCC drug repurposing market was $10.0 Million in 2024. **Q: What is the expected CAGR for the GCC drug repurposing market during the forecast period 2025 - 2035?** A: The expected CAGR for the GCC drug repurposing market during the forecast period 2025 - 2035 is 14.99%. **Q: Which companies are considered key players in the GCC drug repurposing market?** A: Key players in the GCC drug repurposing market include Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc, and Sanofi SA. **Q: What are the different types of drug repurposing segments in the GCC market?** A: The different types of drug repurposing segments in the GCC market include Disease-centric, Target-centric, and Drug-centric, with valuations ranging from $3.0 Million to $18.0 Million. **Q: How do the therapeutic area segments compare in the GCC drug repurposing market?** A: In the GCC drug repurposing market, the therapeutic area segments include Same Therapeutic Area and Different Therapeutic Area, with valuations from $5.0 Million to $24.5 Million. **Q: What types of drug molecules are involved in the GCC drug repurposing market?** A: The types of drug molecules involved in the GCC drug repurposing market are Biologics and Small Molecule, with valuations ranging from $3.0 Million to $33.0 Million. **Q: What does the growth trend indicate for the GCC drug repurposing market?** A: The growth trend indicates a robust expansion for the GCC drug repurposing market, with a projected increase in valuation from $10.0 Million in 2024 to $46.5 Million by 2035. **Q: What is the significance of the drug-centric segment in the GCC market?** A: The drug-centric segment in the GCC market shows a valuation of $15.0 Million, indicating its potential importance in the overall drug repurposing strategy. **Q: How does the market performance of small molecules compare to biologics in the GCC drug repurposing market?** A: In the GCC drug repurposing market, small molecules are projected to have a valuation of $33.0 Million, significantly higher than the $13.5 Million for biologics, suggesting a stronger market performance. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-drug-repurposing-market-52391*